Literature DB >> 4005851

Specificity and inducibility of the metabolic reduction of chromium(VI) mutagenicity by subcellular fractions of rat tissues.

F L Petrilli, A Camoirano, C Bennicelli, P Zanacchi, M Astengo, S De Flora.   

Abstract

The mutagenicity of sodium dichromate in the Ames test was decreased as a consequence of chromium(VI) reduction by tissue postmitochondrial (S-9 or S-12) fractions from untreated rats with the following rank of efficiency: liver; kidney; and lung. The effects of lung preparations were significantly enhanced following the intratracheal administration of high doses (0.25 mg/kg) of dichromate itself, 5 times per week for 4 weeks (i.e., 20 fractionated instillations). No changes were conversely detected following single weekly doses of 1.25 mg/kg for the same period (i.e., four cumulative instillations). The local stimulation of chromium(VI) metabolism was also confirmed by testing the mutagenicity of calcium chromate and chromium trioxide, whereas the metabolism of a number of other activatable or deactivatable mutagens was not significantly affected by intratracheal treatment with chromium(VI). Of three enzyme inducers injected i.p. which modified the spectral properties and/or concentration of cytochromes P-450 in liver and lung microsomes, only Aroclor 1254 proved to stimulate chromium(VI) metabolism in lung cells. In liver cells, Aroclor 1254 and to a lower extent phenobarbital induced chromium(VI) reduction, while 3-methylcholanthrene was ineffective. Pretreatment of rats with these three compounds resulted in a selective induction of the metabolic activation of promutagens [benzo(a)pyrene and its trans-7,8-diol, 2-aminofluorene, aflatoxin B1] and of the metabolic deactivation of direct-acting mutagens [2-methoxy-6-chloro-9-[3-(2-chloroethyl)-aminopropylamino] acridine X 2HCl, epichlorohydrin, 4-nitroquinolino-N-oxide] by S-12 and microsomal fractions. These findings indicate that, in addition to already recognized detoxification mechanisms operating outside target cells (26), specific and inducible chromium-reducing pathways, mediating threshold phenomena in chromium carcinogenesis, do also occur in the intracellular environment.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4005851

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  4 in total

1.  Metabolic reduction of chromium by alveolar macrophages and its relationships to cigarette smoke.

Authors:  F L Petrilli; G A Rossi; A Camoirano; M Romano; D Serra; C Bennicelli; A De Flora; S De Flora
Journal:  J Clin Invest       Date:  1986-06       Impact factor: 14.808

2.  Molecular mechanisms of hexavalent chromium-induced apoptosis in human bronchoalveolar cells.

Authors:  Patrizia Russo; Alessia Catassi; Alfredo Cesario; Andrea Imperatori; Nicola Rotolo; Massimo Fini; Pierluigi Granone; Lorenzo Dominioni
Journal:  Am J Respir Cell Mol Biol       Date:  2005-09-15       Impact factor: 6.914

Review 3.  Metabolic reduction of chromium, as related to its carcinogenic properties.

Authors:  S De Flora; D Serra; A Camoirano; P Zanacchi
Journal:  Biol Trace Elem Res       Date:  1989 Jul-Sep       Impact factor: 3.738

4.  Cytosolic activation of aromatic and heterocyclic amines. Inhibition by dicoumarol and enhancement in viral hepatitis B.

Authors:  S De Flora; C Bennicelli; F D'Agostini; A Izzotti; A Camoirano
Journal:  Environ Health Perspect       Date:  1994-10       Impact factor: 9.031

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.